Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
Noosa News24 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General17 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General19 hours agoPerth man charged after investigation into organised crime and tobacco store attacks